Frazier Life Sciences Acquisition Corp. II filed its first Form 10-Q with the SEC on November 17, 2026, covering the period from August 7, 2026 (inception) through September 30, 2026, disclosing its formation-stage financial condition prior to completing its initial public offering.

Key Highlights

  • Inception date: The company was incorporated on August 7, 2026, as a Cayman Islands exempted company.
  • Net loss: The company reported a net loss of $112,569 for the period from August 7, 2026 (inception) through September 30, 2026.
  • Total assets: As of September 30, 2026, total assets were $437,092, consisting of $162,393 in cash and $274,699 in deferred offering costs.
  • Shareholders' deficit: Total shareholders' deficit stood at $(87,569) as of September 30, 2026.
  • Sponsor note: The company drew $200,000 on a promissory note from its sponsor, Frazier Life Sciences Holdings II, LLC.
  • Post-period IPO: On October 15, 2026, after the balance sheet date, the company consummated its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, generating gross proceeds of $75,000,000.
  • Shares outstanding: As of November 16, 2026, 7,800,000 Class A ordinary shares and 1,875,000 Class B ordinary shares were issued and outstanding.

Formation-Stage Financials and Post-Period IPO for Frazier Life Sciences Acquisition Corp. II

According to the filing, Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) is "a newly organized blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities." The company disclosed that as of September 30, 2026, it had not commenced any operations, and all activity during the reporting period related to its formation and preparation for its initial public offering.

The condensed balance sheet as of September 30, 2026 showed total assets of $437,092, comprised of $162,393 in cash and $274,699 in deferred offering costs. On the liabilities side, the company reported accounts payable of $53,183, accrued expenses of $71,478, accrued offering costs of $200,000, and a promissory note to its sponsor of $200,000, resulting in total current liabilities of $524,661. The company's only equity activity during the period was the issuance of 1,875,000 Class B ordinary shares to its sponsor for $25,000. General, formation, and administrative expenses of $112,569 produced a net loss of the same amount, yielding a basic and diluted net loss per ordinary share of $(0.07) on weighted average shares outstanding of 1,704,545.

The filing also disclosed post-period events. The registration statement for the company's initial public offering was declared effective on October 13, 2026. On October 15, 2026, the company consummated the offering of 7,500,000 Class A ordinary shares at $10.00 per share, generating gross proceeds of $75,000,000 and incurring offering costs of $4,111,319, inclusive of $3,000,000 in deferred underwriting commissions, $750,000 of upfront underwriting discounts, and $361,319 of other offering costs. Simultaneously, the company completed a private placement of 300,000 Class A ordinary shares generating gross proceeds of $3,000,000. The company noted it has not selected any specific business combination target and has not engaged in substantive discussions with any potential target.

What Was Disclosed

The filing covers the company's formation period from August 7, 2026 through September 30, 2026, reporting a net loss of $112,569, a total shareholders' deficit of $(87,569), and no operating activity, along with post-period disclosure of a completed $75,000,000 initial public offering on October 15, 2026.